Strategy announced it purchased 517 Bitcoin for $43.6 million over two weeks, funding about 98.6% of these purchases through common-share sales, with the remainder from cash. Meanwhile, the company repurchased $385.5 million of its preferred stock (STRC) during the same period, spending nearly nine times more on buybacks than on Bitcoin. Michael Saylor hinted at Bitcoin-related activity behind closed doors but did not disclose details. Strategy's capital management separates cash for Bitcoin purchases from reserves used for preferred dividends and debt interest, maintaining significant cash and reserve balances. Investors should watch for future updates on Bitcoin acquisitions and stock repurchase plans.
Strategy's Bitcoin purchase and stock buyback news come as a backdrop to Pluang's cryptocurrency market data. For readers following major cryptocurrencies, 43 of 50 rose and 6 fell as of Oct 24, 2026 01:31 WIB. Notable movers include GRT at Rp434 (+2.29%, 28% Sell / 72% Buy), BNB at Rp13.420.381 (+2.28%, 55% Sell / 45% Buy), and ETC at Rp141.197 (+2.26%, 0% Sell / 100% Buy).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
